Join NextCure for a virtual key opinion leader (KOL) event featuring Ursula Matulonis, MD (NextCure Scientific Advisory Board and Dana Farber Cancer Institute), Rakesh Dixit, PhD, DABT (NextCure Scientific Advisory Board), and Beryl Manning-Geist, MD (Emory University), who will join Company management to discuss first reported clinical efficacy data from NextCure’s Phase 1 dose escalation study of SIM0505, presented as a poster on June 1st at the 2026 American Society for Clinical Oncology Annual Meeting (ASCO 2026).

The event will focus on the unmet need in platinum-resistant ovarian cancer (PROC) and uterine serous carcinoma (USC), two gynecologic malignancies where effective treatment options remain limited. The program will also cover the science behind SIM0505, an investigational antibody-drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload, and the biological rationale for CDH6 as a therapeutic target in these tumors.

A live question and answer session will follow the formal presentations.